

Colorado Molecular Correlates Laboratory
GI Requisition Form
University of Colorado Denver - Anschutz Medical Campus
12705 E. Montview Blvd., Ste. 400, Aurora, CO 80045
Phone: 303-724-4754 Fax: 303-724-3096
CMOCO@ucdenver.edu



ORDERING PHYSICIAN/LABORATORY							PATIENT INFORMATION (please print)							
Physician's Name:							Name (Last, First):							
Practice Name:							Patient Address:							
Address:					(City:			State:	Zip:				
City:		Sta	te: Zip:		F	Phone Numb	er:							
Phone Number:		Fax	Number:		(Gender:			Date of Birth:					
	(D)					□F	Female	☐Male	J G G G H G H G H G H G H G H H H H H H H H H H					
Physician's Signati	ure (Requirea):		Date:		ľ	Patient ID:								
☐ Unless checked here ord	der may be modified based or	n sample quantity & quality.												
				SPECIN	IEN IN	FORMAT	ΓΙΟΝ							
Specimen type/col	lection procedure:				F	Place of Serv		me of Collection/Order:	Date of Collection	1:	Date of IP Discharge:			
Materials Sent:	Unstained/Stained	Slidos with their au	uantity and identifers		(Clinical Histo		Востинен		ICD-10	code(s):			
Specify Block(s) &	Oristalineu/Stalineu	Sildes with their qu	iantity and identifiers											
				TE	ST SEI	_ECTION								
GI PANEL ⁴	. 5			I L	31 3LL	LCTION								
l			Chal	angiocarcinoma				□ NGS Mutation 3	Costing (gono list)					
Microsate	Carcinoma ¹ ellite instability and		Fu	sions: FGFR2/3, R		, , ,								
If negati	s: KRAS, NRAS, I ve for the RAS/RA		_	tations: IDH1, BR/	AF, KRA	ა		NGS Fusion Te						
If RAS	ERBB2 /RAF negative an		to: Mid	ric Carcinoma crosatellite instabili	ity analys									
If MSI-H	ions: NTRK1/2/3, and MLH1/PMS2	loss (by IHC),	_	SH: ERBB2					Fusion Testing (be billed/charged)	gene lis	<u>t</u>)			
	promoter hyperm ere to exclude MS			d KRAS (non-NGS	S)		Targeted Fusion Testing							
Pancreatic	Pancreatic Carcinoma ^{2, 3}							Fusion NGS for NRG1, FGFR1/2	ALK, ROS1, RET, I 2/3	NTRK1/2	2/3,			
Microsate	ellite instability and : KRAS (by NGS),			edness of multipliple primary vs. n				NTRK1/2/3 Fusi	on Testing					
If negativ	ve for KRAS muta ns: NRG1, NTRK1	tion, reflex to:	Mu	tations: Full panel ns to compare:		NTRK1/2/3 + RET Fusion Testing								
	ons: BRAF, ERBE	•												
GIST	s: KIT, PDGFRA,	RDAE NE1 SC	DHA/R/C/D											
If negativ	re for the above gos: NTRK1/2/3, RE	enes, reflex to:												
Add-on gen	•	= 1												
□AKT1	BRAF	☐ EGFR	☐ FGFR1	GNAS	□ĸD	DR .	□ NO7	TCH1 PTEN	SMAD4	□ 7	TP53			
□ALK	□ CDH1	☐ ERBB2	☐ FGFR2	☐ H3F3A	□ KI		NRA		SMARCB1	ı 🗆 v	/HL			
□ APC		☐ ERBB3	☐ FGFR3	∐ HNF1A	□ KR				□ SMO					
□ AR □ ATM	□ CDKN2A □ CTNNB1	☐ ERBB4 ☐ ESR1	☐ FOXL2 ☐ GNA11	∐HRAS □IDH1	Ш МА □ МЕ		☐ PIK: ☐ PIK:	<u> </u>	□ SRC □ STK11					
□ ATM □ AURKA	DDR2	\Box ESK I	☐ GNATT	□ IDH1 □ IDH2	□ ML				☐ TERT					
FISH ANALYS	219			MUTATIONAL	ΔΝΔΙΝ	VSIS (Tar	natad A	lecave)	MSI					
HER2/neu	_			BRAF		LH1 promote	_			satellite	Instability			
				KRAS	□ NF	RAS			_					
			om Outside Ins □ check here if available			Notes/Spe	cial Req	uests:						
Consultat	tion and Repor	rt on Referred	Slides and/or											
(surgical pathology consultation for diagnosis) All tests include physician interpretation and report unless checked here; contact lab for service eligibility for														
technical only. 1. If quantity insufficient for NGS testing, KRAS, BRAF and NRAS will be tested via alternate methods,														
as feasible.														
2. If quantity insufficient for NGS testing, KRAS will be tested via alternate methods, as available.														
3. If quantity insufficient for extensive NGS testing, BRCA1/2 will not be reported. 4. Fusions by NGS will be issued in a separate report. If insufficient for fusion by NGS, other														
	testing will not be ca			5.511 by 1400, 00161										
5. Only indicate	d genes will be repo	rted. Select 'add-o	n gene' if desired.					9.199						

BILLING INFORMATION										
Self-Pay Insurance	Insured's Relation to Patient: ☐ Self	Insurance (For non-University of Colorado Hospital patients, please see below):								
☐ Physician/Lab	☐ Spouse	Insured's Name (if not patient):								
☐Grant	Dependent									
Claims Address:			City:		State:	Zip:				
Insurance ID#:			Group Name:		Group Number:					
Grant Info (Grant Name, Number, Study Coordinator, PI, and SpeedType):										
BILLING INFORMATION FOR PATIENTS OUTSIDE THE UNIVERSITY OF COLORADO HOSPITAL										
laboratories to bill Medicare directly for molecular pathology tests (CPT codes 81105-81479), which are excluded from the OPPS packaging policy, if the specimen was collected from a hospital outpatient encounter. Payers following this rule include: Medicare, Medicare HMOs, VA and United Healthcare. No such rule has been implemented for specimens collected from hospital inpatients. IN-PATIENT STATUS AT TIME OF COLLECTION AND/OR ORDER										
TESTING ORDERED WITHIN 14-DAYS FROM THE DATE OF DISCHARGE: The technical component of any/all services will be billed back to your institution (please provide BILL TO INFORMATION below). The professional interpretation will be billed to insurance.										
TESTING ORDERED 14-DAYS AFTER THE DATE OF DISCHARGE: Any/All services will be billed to insurance.										
OUT-PATIENT STATUS AT TIME OF COLLECTION AND/OR ORDER										
TESTING ORDERED WITHIN 14-DAYS FROM THE DATE OF COLLECTION: The technical components of microdissection (88381), FISH (88271-88275) and IHC (88341-88342,										
88360-88361) will be billed back to your institution (please provide BILL TO INFORMATION below). The professional interpretation will be billed to insurance. TESTING ORDERED 14-DAYS AFTER THE DATE OF COLLECTION: Any/All services will be billed to insurance.										
TECHNICAL COMPONENT - BILL TO INFORMATION										
Institution Name:			Billing Person Name:							
Address:										
City:			State:	Zip:						
Phone:			Fax:							
Billing Person E-mail:			•							